Guía Farmacoterapéutica de Atención Primaria - Osakidetza (PDF)

82 Sistema Cardiovascular Grupo C.
◗ Fioravanti M, Flicker L. Efficacy of nicergoline in dementia and other age associated forms of cognitiva impairment
(Cochrane Review). In: The Cochrane Library, Issue 1, 2003. Oxford. Update Software.
◗ Lopez-Arrieta J, Nimodipine for primary degenerative, mixed and vascualr dementia (Cochrane Review). In: The
Cochrane Library, Issue 1, 2003. Oxford. Update Software.
◗ Fioravanti M, Yanagi M. Cytidinediphosphocholine (CDP choline) for cognitive and behavioural disturbance associated
with chronic cerebral disorders in the elderly (Cochrane Review). In: The Cochrane Library, Issue 1, 2003. Oxford.
Update Software.
◗ Diosmine. Gelma CR, Rumarck BH, hess AJ, editors. DRUGDEX Informatio System MiICROMEDEX inc, Englewood,
Colorado, 2001
◗ Drug Therapy for Peripheral Vascular Disease. A national Guideline. Scottish Intercollegiate Guidelines Network. Nº
27. July 1998. Disponible en: http://www.show.scot.nhs.uk/sign/guidelines/published/index.html
◗ Malatia vascular perifèrica. Butlletí d’informació terapéutica del Serbei Cátala de la Salut 2002;14(2). Disponible en:
http://www.icf.uab.es/informacion/boletines/bit_c.htm
◗ Citicoline. Gelma CR, Rumarck BH, hess AJ, editors. DRUGDEX Informatio System MiICROMEDEX inc, Englewood,
Colorado, 2001
◗ Moher D, Pham B, Ausejo M, Saenz A, Hood S, Barber GG. Pharmacological management of intermittent
claudication: a meta-analysis of randomised trials. Drugs 2000;59(5):1057-70.
◗ Malatia vascular perifèrica. Butlletí d´informació terapèutica. Departament de Sanitat i Seguretat Social de la
Generalitat de Catalunya, 2002;14(2):7-10.
◗ Managing peripheral arterial disease in primary care. DTB 2002;40(1):5-8.
◗ Scottish Intercollegiate Guidelines Network. Drug therapy for peripheral vascular disease. A National Guideline SIGN
1998.
◗ Cardiovascular disorders. Peripheral arterial disease. Clinical Evidence 2003. Disponible en: http://pco.ovid.com
Nota de la AEMPS
Vasoprotectotres
◗ De Miguel Gallo V, Vargas Castrillón E. Venotónicos en el tratamiento de la insuficiencia venosa crónica: una reviión
sistemática. Inf Ter Sist Nac Salud 1997;21(2):33-40.
◗ Redactores Fisterra. Guía dearteriopatía periférica 2002,2(16). Consulta realizada: 8/5/03. Disponible en http://
www.fisterra.com/guias2/iam.htm.
◗ Agentes flebotónicos de administración oral. Inf Ter Sist Nac Salud 2002;26(5):136-7.
◗ Haemorrhoids. Prodigy Guidance, 2002.
◗ Nota de la Agencia Española del Medicamento
Hipolipemiantes
◗ NHLBI: The Third Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol
(Adult Treatment Panel III) NCEP III
◗ Shepherd J, Blauw GJ, Murphy MB, et al. PROSPER study group. Pravastatin in elderly individuals at risk of vascualr
disease (PROSPER): a randomized controlled trial. Lancet 2002;360:1623-30
◗ The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major Outcomes in
moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The
Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT) JAMA 2002;288:2998-
3007
◗ Sever PS, Dhalof B, Poulter NR, et al. ASCOT investigators. Prevention of coronary and stroke events with
atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the